Development and Preliminary Mechanistic Evaluation of a Novel Liposomal QS-21 and CpG ODNs Adjuvant System for Enhancing Vaccine Immunogenicity
Open Access
Abstract
Developing potent adjuvants is critical for enhancing vaccine efficacy, particularly for subunit antigens. Background/Objectives: This study evaluates a novel composite adjuvant system combining liposomal QS-21 and CpG ODNs to enhance vaccine-induced immunogenicity, particularly Th1-type cellular immunity. Methods: To mitigate QS-21’s hemolytic toxicity and ensure precision delivery, a stable liposomal formulation was developed. Mice models were established using varicella-zoster virus (VZV) glycoprotein E (gE) or ovalbumin (OVA) as antigens to evaluate humoral and cellular immune responses. Results: Immunization with gE protein formulated with this novel adjuvant synergistically triggered robust immune responses, outperforming single adjuvants and the combination of QS-21/MPL. Across broad dose ranges, it induced higher Th1-type cellular immunity and comparable humoral immunity relative to AS01B. Mechanistic studies revealed that the adjuvant significantly enhances the recruitment of dendritic cells (DCs), monocytes, and neutrophils to draining lymph nodes (dLNs) while upregulating co-stimulatory molecules CD40 and CD86 on DCs. Furthermore, the formulation triggered robust, transient increases in Th1-associated cytokines (IFN-γ, IL-12) and chemokines (CXCL9, CXCL10) across the injection site, serum, and dLNs. Conclusions: These findings indicate that the liposomal QS-21 and CpG ODNs system is a highly effective platform for promoting robust Th1-biased immunity, offering a promising adjuvant candidate and a solid experimental foundation for developing next-generation vaccines requiring potent cellular immunity.Keywords
Funding Information
- Special Fund for Science and Technology Programs of Jiangsu Province (BE2022685)
This publication has 27 references indexed in Scilit:
- Advancements in saponin-based vaccine adjuvantsMedicinal Chemistry Research, 2025
- Resolving adjuvant mode of action to enhance vaccine efficacyCurrent Opinion in Immunology, 2022
- Peptide-Based Vaccines: Current Progress and Future ChallengesChemical Reviews, 2019
- Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A reviewPhytomedicine, 2019
- Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticityVaccine, 2019
- Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adultsVaccine, 2016
- In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunityNature Medicine, 2015
- Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)Vaccine, 2014
- Advances in saponin-based adjuvantsVaccine, 2009
- Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant functionVaccine, 1995